Mary Fjerstad.

And Figure 1Body 1Rates of SERIOUS ILLNESS after Medical Abortion among Sufferers in Two Groups of Planned Parenthood Health Centers. The 93 percent relative decrease in the rate of serious illness between Period 1 and Period 4 was an absolute reduction of 0.86 per 1000 . The price of serious infection declined significantly between Intervals 1 and 2 and between Periods 2 and 3 . Between Periods 3 and 4, the change in the rate of serious infection was not significant . Between Intervals 1 and 2, there were significant declines in the rates of serious illness in both mixed group 1 and Group 2, however the relative decline was considerably greater in Group 2 than in Group 1 . Between Periods 2 and 3, there were additional declines in both Group 1 and Group 2 , but the relative declines didn’t differ considerably ; the mixed relative risk in Period 3 as compared with Period 2 was 0.24 .About the Bristol-Myers Squibb/Pfizer Collaboration In 2007, Pfizer and Bristol-Myers Squibb entered right into a worldwide collaboration to build up and commercialize apixaban, an investigational oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb’s long-position strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and experience in this field. About Bristol-Myers Squibb Bristol-Myers Squibb is normally a global biopharmaceutical company whose objective is to discover, develop and deliver innovative medicines that help sufferers prevail over serious diseases.